Verzenio
Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data
July 31, 2019Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma
Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …
Japan’s health ministry warns of serious side effects of Lilly’s Verzenio
May 23, 2019Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma
Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …
Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer
October 3, 2018Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma
The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged. The therapy …
FDA expands indication of Lilly’s Verzenio in advanced breast cancer
February 27, 2018Manufacturing and Production, Sales and Marketing Cancer, Eli Lilly, FDA, Verzenio, breast cancer, pharma
Eli Lilly is celebrating the news that its cyclin-dependent kinase (CDK) 4 & 6 inhibitor Verzenio (ademaciclib) has received approval …
Lilly receives FDA breast cancer pill approval, doubts remain
September 29, 2017Medical Communications, Sales and Marketing Eli Lilly, Verzenio, biotech, drugs, pharma, pharmaceutical
Eli Lilly has received an important approval for its breast cancer treatment, Verzenio. The drug will be the third to …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
